The ITM Rhenium-SCT™ is the new generation of non-invasive skin cancer therapy, provided by ITM OncoBeta GmbH - predominantly to patients with large and difficult to treat skin tumours .

The ITM Rhenium SCT™ including the relevant system components are currently undergoing final CE-certification procedures, awaiting the CE mark as a Class II b medical device. The preliminary research results obtained are highly encouraging for the treatment of non-melanoma skin cancer indications showing good clinical clearance after 3 months. The empirical data collected is positive and the Company and researchers are convinced that we will be able to determine the therapy as a viable treatment option in our respective indication universe. Here, further clinical evaluations are planned. Once full market and regulatory approvals have been received, pilot operations in leading centres in Europe are currently in preparation.

For further information please refer to: